Frontlight ResearchEarly access
CompletedNo phase
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
Key facts
- Who runs it
- University of North Carolina, Chapel Hill
- Where
- Aurora, Bethesda, Chapel Hill, Palo Alto, Seattle, and St Louis, United StatesSee the 6 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Completed
- People taking part
- 436 people enrolled
- Started
- 1 Dec 2020
- Ended
- 6 Aug 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Genetic Testing for PCD or PID
- Unaffected Family Member Genetic Testing
- Record updated
- 21 August 2025
Who can take part
- Age
- 5 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- General Criteria
- Age 5-45 years
- Male and Female Subjects
- All races and ethnicities; Major Clinical Criteria
- Bronchiectasis in > 1 lobe; Minor Clinical Criteria, Lung
- Neonatal respiratory distress (in term neonates with O2 requirement)
- Chronic wet cough (year-round for at least 12 months)
- Recurrent episodes of bacterial bronchitis
- Recurrent pneumonia (confirmed on chest x-ray)
- Respiratory non-tuberculous mycobacteria (NTM) (documented respiratory NTM culture); Minor Clinical Criteria, Other
- Chronic nasal congestion
- Recurrent/chronic paranasal sinusitis
- Ongoing middle-ear disease and/or tympanostomy tube placement at age ≥ 4 years
- Organ laterality defect
- Low nasal nitric oxide (< 77 nL/min) (by plateau measurement)
- Confirmed family history of PID or PCD
Who cannot take part
- Conditions known to be commonly associated with bronchiectasis, such as prior mycobacterium tuberculosis
- Post-lung or heart transplant, or other conditions requiring immunosuppression therapy
- Other confounding features, such as lung disease due to prematurity (born < 28 weeks gestation) or HIV
- Have not had standard clinical evaluation to address other potential causes of chronic oto-sino- pulmonary disease, particularly cystic fibrosis, aspiration or airway anatomic abnormalities
- Anyone who has a confirmed genetic diagnosis of PCD or PID
- Cystic Fibrosis
- Alpha-antitrypsin deficiency in adults (18 years and older)
- Congenital upper or lower airway anomalies
- Neurological compromise and evidence of recurrent aspiration
Other criteria
- Pediatric subjects (aged 5-17 years): Inclusion criteria include the major criterion (bronchiectasis in > 1 lobe on current or chest CT in previous 24 months, if available for review), plus one minor criterion, or two minor criteria, if bronchiectasis is not present, (including at least 1 "lung" minor criteria)
- Adult subjects (aged 18-45 years): Inclusion criteria include the major criteria (bronchiectasis in > 1 lobe on current or chest CT in previous 36 months, if available for review), plus one minor criterion, or three minor criteria, if bronchiectasis is not present, (including at least 1 "lung" minor criteria)
Where in United States
Also in 1 other country, 2 sites
- Children's Hospital ColoradoAurora, United States
- National Heart Lung and Blood InstituteBethesda, United States
- University of North Carolina at Chapel HillChapel Hill, United States
- Stanford UniversityPalo Alto, United States
- Seattle Children's HospitalSeattle, United States
- Washington University in St. LouisSt Louis, United States
About the trial
What the trial wants to find out
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
The 2 groups in the trial
- Affected Participants
Subjects who have suppurative lung disease without a known genetic diagnosis
Treatment: Genetic Testing for PCD or PID
- Unaffected Family Members
Unaffected family members may be enrolled in the study for collection of DNA only
Treatment: Unaffected Family Member Genetic Testing
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 21 August 2025